Metrics as of 10/14/2026, 11:36 PM (Berlin time), refresh in progress.
Lite Strategy Stock
Lite Strategy, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Justin J. File
- Employees
- 5
- Market cap
- $36 M
- IPO
- 18/12/2003
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The…
Lite Strategy stock: price history
1D
-3.3%
1W
-7.9%
1M
+1.7%
6M
-2.5%
YTD
-11.4%
1Y
-46.6%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~68% stronger price swings than usual
Ask the agents about Lite Strategy
Lite Strategy stock metrics
P/E
-0.13
P/B
0.97
EV/EBITDA
-2.45
RETURN ON EQUITY
-31.3%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.6%
FLOAT SHARES
23,593,632
AVG. DAILY VOLUME (30D)
847,015
Insider transactions (SEC)
Flynn James P
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Lite Strategy stock
What does Lite Strategy do?
Lite Strategy, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Justin J. File, the company employs around 5 people.
The IPO was on 18/12/2003; the stock trades on NASDAQ under the ticker LITS.
When does Lite Strategy report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly 68% stronger than usual.
Does Lite Strategy pay a dividend?
Yes. The last dividend was US$1.75 per share, ex-date 16/11/2023, paid on 06/12/2023.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Lite Strategy?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Lite Strategy stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lite Strategy against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.